GSK's Headline Results From Interim Analysis Of DREAMM-8 Phase 3 Head-To-Head Trial Of Blenrep Plus Pomalidomide Plus Dexamethasone, Versus Standard Of Care As Second Line Treatment For Relapsed/Refractory Multiple Myeloma Show Trial Met Primary Endpoint

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!